The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
XL BCR/ABL1 plus
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl
The XL BCR/ABL1 plus probe is specific for the t(9;22). The orange labeled probe hybridizes to an extended region spanning the ABL1 locus on 9q34, and a green labeled probe hybridizes specifically to extended regions spanning the BCR gene on 22q11. The probe is designed as a dual-color, dual-fusion assay.
Chronic myelogenous leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22, called the Philadelphia (Ph) chromosome. The same translocation can also be found in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) with some variation in the breakpoint region. Glivec (Imatinib Mesylate) treatment targeting the BCR/ABL active tyrosine kinase has become a major drug in treating CML, gastrointestinal stromal tumors, and other cancers.
- Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms (CML/MPN)
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myelogenous Leukemia (AML)
Two green (2G) and two orange signals (2O).
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange fusion signals (2GO).
- Dewald et al (1998) Blood 91:3357-3365
- Huntly et al (2003) Blood 102:1160-1168
- Primo et al (2003) Leukemia 17:1124-1129